NBT Bank N.A. Makes New $811,000 Investment in Novo Nordisk A/S $NVO

NBT Bank N.A. purchased a new position in Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 21,400 shares of the company’s stock, valued at approximately $811,000.

Several other hedge funds and other institutional investors have also modified their holdings of NVO. Root Financial Partners LLC bought a new position in Novo Nordisk A/S in the third quarter worth about $32,000. Cardinal Capital Management boosted its stake in Novo Nordisk A/S by 11.8% in the third quarter. Cardinal Capital Management now owns 56,187 shares of the company’s stock valued at $2,130,000 after acquiring an additional 5,926 shares during the period. Foster Victor Wealth Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 7.3% during the third quarter. Foster Victor Wealth Advisors LLC now owns 12,705 shares of the company’s stock valued at $488,000 after purchasing an additional 863 shares during the last quarter. Flavin Financial Services Inc. grew its holdings in shares of Novo Nordisk A/S by 4.0% during the third quarter. Flavin Financial Services Inc. now owns 12,235 shares of the company’s stock valued at $464,000 after purchasing an additional 475 shares during the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. raised its position in shares of Novo Nordisk A/S by 55.8% during the 3rd quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 333,620 shares of the company’s stock worth $12,648,000 after purchasing an additional 119,545 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $39.05 on Friday. The firm’s 50 day moving average is $41.92 and its two-hundred day moving average is $43.99. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The firm has a market capitalization of $174.34 billion, a P/E ratio of 9.55, a PEG ratio of 1.34 and a beta of 0.76. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. Analysts anticipate that Novo Nordisk A/S will post 3.42 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were given a $0.5786 dividend. The ex-dividend date was Monday, August 17th. This represents a yield of 258.0%. This is a decrease from Novo Nordisk A/S’s previous dividend of $1.2751. Novo Nordisk A/S’s payout ratio is 20.05%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Awiqli as the first and only once-weekly insulin for children aged 10 and older with Type 2 diabetes. The approval expands Novo Nordisk’s insulin offering and could support long-term sales growth. FDA approves Awiqli for children
• Positive Sentiment: Novo Nordisk is expanding its use of OpenAI’s Rosalind platform for drug discovery, including target identification, molecule design and clinical-trial analytics. Stronger AI capabilities could improve research productivity and support the company’s future pipeline, although financial benefits are likely longer term. Novo Nordisk expands AI drug discovery
• Neutral Sentiment: The company scheduled its next earnings release for November 3. The report will be an important near-term catalyst as investors assess demand, guidance, competitive pressure and the outlook for its GLP-1 portfolio. Novo Nordisk sets November 3 results date
• Neutral Sentiment: Pipeline coverage highlights three regulatory tracks and the upcoming earnings date, keeping attention focused on approval opportunities and clinical progress. These developments could improve sentiment, but their impact depends on regulatory outcomes and data quality. Novo Nordisk pipeline scorecard
• Negative Sentiment: Analysts continue to compare Novo Nordisk unfavorably with Viking Therapeutics, arguing that Viking’s obesity-drug pipeline may offer greater upside. The comparison reinforces concerns that Novo Nordisk faces increasing competition despite its scale and established products. NVO versus VKTX obesity-stock comparison
• Negative Sentiment: Recent commentary points to mixed CagriSema subgroup data and worries about the U.S. market, including competition from Eli Lilly. These issues offset the support from Novo Nordisk’s share buyback program and remain key risks for valuation. Novo Nordisk buyback and CagriSema update

Analyst Ratings Changes

Several analysts recently issued reports on the company. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Thursday, September 10th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Friday, October 9th. Jefferies Financial Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a research report on Tuesday, September 29th. Finally, DZ Bank reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $59.44.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.